TICKERNERD
Menu
GEHCGEHCHealthcare · Medical Devices

GEHC Stock Forecast: GE Healthcare Technologies, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$70
−1.20% on the day

The 19 Wall Street analysts covering GE Healthcare Technologies, Inc. hold a median 12-month price target of $83 — +19.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 2 Sept 2026 — in the upper half.

Market cap
$31.8B
Ticker Nerd rank
65 / 100
Median analyst target
$83
Analysts covering
19
Revenue$5.3B+5.8% y/y
Operating income$738.0M
Net income$573.0M
Free cash flow$68.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−0.0%
YTD
−14.9%
1Y
−3.5%
From 52W high
−20.8%
From 52W low
+17.3%
$59
$88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GEHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GE Healthcare Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Volatility
91
Issuance
85
Revisions
63
Quality
59
Growth
50
Momentum
47
Accruals
37
Size
7

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GEHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GEHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100Oct 25Jan 26Apr 26Jul 26GEHCHigh $96Median $83Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
14 Buy5 Hold0 Sell
Low $70Median $83High $96

The green dot is the last close — the median target sits +19.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
19 Aug 2026BTIGReiteratesBuy$79
31 July 2026UBSMaintainsNeutral—
31 July 2026UBSMaintainsNeutral$67 → $73
30 July 2026CitigroupMaintainsNeutral—
30 July 2026CitigroupMaintainsNeutral$69 → $75
30 July 2026Evercore ISI GroupMaintainsOutperform$80 → $84
30 July 2026Evercore ISI GroupMaintainsOutperform—
30 July 2026Wells FargoMaintainsOverweight—
30 July 2026Wells FargoMaintainsOverweight$75 → $85
29 July 2026BTIGMaintainsBuy—
29 July 2026BTIGMaintainsBuy$75 → $79
17 July 2026Hovde GroupInitiatesMarket Perform—
16 July 2026UBSMaintainsNeutral—
16 July 2026UBSMaintainsNeutral$69 → $67
9 July 2026BMO CapitalInitiatesMarket Perform—
23 June 2026RBC CapitalInitiatesOutperform—
21 May 2026UBSUpgradeNeutral—
30 Apr 2026BarclaysMaintainsEqual-Weight—
30 Apr 2026CitigroupMaintainsNeutral—
30 Apr 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GEHC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GEHC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, GE Healthcare Technologies, Inc. returned −3.5% against +21.4% for the S&P 500, dividends included.

GEHC vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26GEHCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GEHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.1%
Analysts raising
15
Analysts cutting
1
Fundamentals

GE Healthcare Technologies, Inc. (GEHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.2×

Cheaper than 44% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
2.9×

Cheaper than 35% of US stocks

EV / EBITDA
11.4×

Cheaper than 33% of US stocks

Growth & margins
Revenue growth (YoY)
5.8%

Higher than 41% of US stocks

Earnings growth (YoY)
15.4%

Higher than 54% of US stocks

Gross margin
41.2%

Higher than 52% of US stocks

Operating margin
15.0%

Higher than 72% of US stocks

Net margin
9.3%

Higher than 68% of US stocks

Returns & dividend
Return on equity
19.4%

Higher than 80% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
0.2%

Higher than 3% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GE Healthcare Technologies, Inc. (GEHC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GE Healthcare Technologies, Inc. has a market value of $31.8B and an enterprise value of $40.9B.

  • Revenue in the twelve months to 30 June 2026: $21.3B. The latest quarter grew 5.8% year on year.

  • Net income over the same four quarters: $2.0B, a 9.6% net margin.

  • Diluted earnings per share, trailing twelve months: $4.36.

  • Free cash flow in the twelve months to 30 June 2026: $1.6B.

  • GE Healthcare Technologies, Inc. spent $400.0M on share buybacks and $64.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 451.7M.

  • Trailing P/E: 16.2×; forward P/E: 13.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.20%, paying out 3% of earnings.

  • GE Healthcare Technologies, Inc. employs 54,000 people — $394K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 2 Sept 2026

Data provided by Twelve Data

Peers

GEHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GEHCGE Healthcare Technologies, Inc.$31.8B
65
DXCMDexCom, Inc.$34.6B
99
STESTERIS Plc (Ireland)$22.4B
87
EWEdwards Lifesciences Corp.$52.3B
90
ZBHZimmer Biomet Holdings, Inc.$19.7B
91
BSXBoston Scientific Corp.$71.7B
58
PENPenumbra, Inc.$12.7B
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GE Healthcare Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GEHC news & analysis

GEHC Wins CE Mark for Photonova Spectra, Expands International Reach

Zacks Investment Research · 2 Sept 2026positive

GE HealthCare's Photonova Spectra received CE Mark approval, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets. This extends the company's international reach for this product.

Why it matters — GEHC watchers would care because the CE Mark broadens the addressable market for the Photonova Spectra CT technology beyond existing regions, strengthening the company's international footprint.

GEHC vs. HAE: Which Stock Is the Better Value Option?

Zacks Investment Research · 31 Aug 2026neutral

Zacks Investment Research published an article comparing GE HealthCare Technologies (GEHC) and Haemonetics (HAE) as value investing options in the Medical - Products sector. The piece examines which of the two stocks is more attractive to value-oriented investors.

Why it matters — GEHC watchers would gain insight into how the company's stock compares with a peer on value metrics, informing their assessment of GEHC's relative investment appeal.

GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems

Zacks Investment Research · 31 Aug 2026positive

GE HealthCare has expanded its Vivid cardiovascular ultrasound portfolio with three new next-generation systems. The systems feature AI tools and cSound imaging technology designed for use across varied care settings.

Why it matters — The product line expansion signals continued innovation and portfolio growth in GEHC's cardiovascular ultrasound segment, a key area of its diagnostics business.

GE HealthCare's Photonova™ Spectra gains CE Mark, expanding international access

Business Wire · 31 Aug 2026positive

GE HealthCare received CE Mark for its Photonova Spectra, an advanced photon-counting computed tomography system featuring its proprietary Deep Silicon detector technology. This regulatory milestone expands access and enables clinical adoption of the technology in CE Mark-observing countries.

Why it matters — This regulatory approval broadens international market access for one of GE HealthCare's advanced CT products, potentially supporting growth in its imaging portfolio.

Why Is GE HealthCare (GEHC) Up 3.6% Since Last Earnings Report?

Zacks Investment Research · 28 Aug 2026positive

GE HealthCare (GEHC) reported earnings 30 days ago, and its stock is up 3.6% since that report. The article poses the question of what may come next for the stock following the earnings release.

Why it matters — A GEHC watcher would care because the post-earnings price movement offers a snapshot of market reaction to the company's latest results.

FAQ

Frequently asked questions about GEHC stock

What is the GEHC stock price forecast for 2026-2027?

The 19 Wall Street analysts covering GE Healthcare Technologies, Inc. have a median 12-month price target of $83, with estimates ranging from $70 to $96. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GEHC stock a buy right now?

Of the 19 analysts covering GE Healthcare Technologies, Inc., 14 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GE Healthcare Technologies, Inc. 65 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GEHC?

As at 2 Sept 2026, GE Healthcare Technologies, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will GEHC stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +19.1% from the last close, and Ticker Nerd's factor model ranks GE Healthcare Technologies, Inc. 65 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GEHC stock forecast for 2030?

No analyst covering GE Healthcare Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GEHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $96 over the next 12 months.

How has GEHC stock performed over the past year?

GE Healthcare Technologies, Inc. returned -3.5% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GE Healthcare Technologies, Inc. do?

GE HealthCare Technologies Inc. is a global medical technology and diagnostics company that develops imaging systems, ultrasound equipment, patient monitoring and anesthesia solutions, and pharmaceutical diagnostics products.

What is the latest news on GEHC?

The most recent item we track (Zacks Investment Research, 2 Sept 2026): "GEHC Wins CE Mark for Photonova Spectra, Expands International Reach". GE HealthCare's Photonova Spectra received CE Mark approval, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets. This extends the company's international reach for this product.

Company

About GE Healthcare Technologies, Inc.

GE HealthCare Technologies Inc. is a global medical technology and diagnostics company that develops imaging systems, ultrasound equipment, patient monitoring and anesthesia solutions, and pharmaceutical diagnostics products. Its portfolio supports hospitals, health systems, and clinical providers with tools used in diagnosis, treatment, and patient care across routine and complex medical settings. GE HealthCare also offers software, digital workflows, and service capabilities that help healthcare organizations manage equipment, improve clinical efficiency, and integrate data across care environments. The company’s main business areas include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, reflecting its broad role in modern healthcare infrastructure. Headquartered in Chicago, Illinois, GE HealthCare focuses on technologies and services that are widely used in medical imaging, bedside monitoring, and diagnostic procedures worldwide.

CEO Mr. Peter J. Arduini · 54,000 employees · United States · https://www.gehealthcare.com